UA82503C2 - Жидкая композиция белка, который связывает фактор некроза опухолей - Google Patents

Жидкая композиция белка, который связывает фактор некроза опухолей Download PDF

Info

Publication number
UA82503C2
UA82503C2 UAA200508323A UA2005008323A UA82503C2 UA 82503 C2 UA82503 C2 UA 82503C2 UA A200508323 A UAA200508323 A UA A200508323A UA 2005008323 A UA2005008323 A UA 2005008323A UA 82503 C2 UA82503 C2 UA 82503C2
Authority
UA
Ukraine
Prior art keywords
composition according
tumor necrosis
necrosis factor
tme
buffer
Prior art date
Application number
UAA200508323A
Other languages
English (en)
Ukrainian (uk)
Inventor
Фабрицио Самаритани
Рио Алессандра Дель
Рита Агостинетто
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of UA82503C2 publication Critical patent/UA82503C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение касается стойкой фармацевтически приемлемой водной композиции TNF-связующего белка, который содержит ТВР-1 как TNF-связующий белок, буфер и изотонический агент, причем буфером является фосфатный буфер, который удерживает уровень рН в пределах от 6 до 7, а изотоническим агентом является хлорид натрия или маннит.
UAA200508323A 2003-02-28 2004-11-02 Жидкая композиция белка, который связывает фактор некроза опухолей UA82503C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100505 2003-02-28
PCT/EP2004/050118 WO2004075918A1 (en) 2003-02-28 2004-02-11 Liquid formulations of tumor necrosis factor-binding proteins

Publications (1)

Publication Number Publication Date
UA82503C2 true UA82503C2 (ru) 2008-04-25

Family

ID=32921619

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200508323A UA82503C2 (ru) 2003-02-28 2004-11-02 Жидкая композиция белка, который связывает фактор некроза опухолей

Country Status (21)

Country Link
US (3) US8937045B2 (ru)
EP (1) EP1603596B1 (ru)
JP (1) JP4980048B2 (ru)
KR (1) KR20050105486A (ru)
CN (1) CN100563712C (ru)
AR (1) AR043418A1 (ru)
AT (1) ATE394123T1 (ru)
BR (1) BRPI0407649A (ru)
CA (1) CA2515539A1 (ru)
DE (1) DE602004013557D1 (ru)
EA (1) EA009079B1 (ru)
ES (1) ES2304602T3 (ru)
HR (1) HRP20050706A2 (ru)
IL (1) IL170414A (ru)
MX (1) MXPA05009135A (ru)
NO (1) NO20054440L (ru)
PL (1) PL213501B1 (ru)
RS (1) RS51041B (ru)
UA (1) UA82503C2 (ru)
WO (1) WO2004075918A1 (ru)
ZA (1) ZA200506504B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
CN103930124B (zh) 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
BR112014009146A8 (pt) 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
ES2936387T3 (es) 2011-10-31 2023-03-16 Hoffmann La Roche Formulaciones de anticuerpos anti-il13
HK1209343A1 (en) 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
SI2895188T1 (en) 2012-09-11 2018-05-31 Coherus Biosciences, Inc. CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
MX366622B (es) 2012-10-26 2019-07-16 Lupin Atlantis Holdings Sa Composicion farmaceutica estable de la proteina de fusion tnfr:fc.
MX2016016148A (es) 2014-06-26 2017-04-25 Maruishi Pharma Preparacion de rocuronio con estabilidad mejorada.
RU2724900C1 (ru) * 2019-10-24 2020-06-26 Маруиси Фармасьютикал Ко., Лтд. Препарат рокурония с улучшенной стабильностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
DK0839046T3 (da) * 1995-07-14 2002-02-18 Applied Research Systems TNF-receptor og steroidhormon i en kombinationsterapi
EP0910413A2 (en) * 1996-05-08 1999-04-28 F. Hoffmann-La Roche Ag TREATMENT OF ASTHMA WITH TNFR-Ig
WO1998024463A2 (en) * 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
SI1478394T1 (sl) * 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM

Also Published As

Publication number Publication date
US8937045B2 (en) 2015-01-20
JP2006519210A (ja) 2006-08-24
ZA200506504B (en) 2006-12-27
PL378290A1 (pl) 2006-03-20
CA2515539A1 (en) 2004-09-10
RS20050662A (sr) 2007-11-15
CN1774266A (zh) 2006-05-17
ATE394123T1 (de) 2008-05-15
US9512215B2 (en) 2016-12-06
RS51041B (sr) 2010-10-31
EP1603596A1 (en) 2005-12-14
EA200501230A1 (ru) 2006-04-28
US20170020960A1 (en) 2017-01-26
US20150098950A1 (en) 2015-04-09
AR043418A1 (es) 2005-07-27
PL213501B1 (pl) 2013-03-29
WO2004075918A1 (en) 2004-09-10
DE602004013557D1 (de) 2008-06-19
EA009079B1 (ru) 2007-10-26
JP4980048B2 (ja) 2012-07-18
IL170414A (en) 2009-11-18
ES2304602T3 (es) 2008-10-16
EP1603596B1 (en) 2008-05-07
HK1085677A1 (zh) 2006-09-01
HRP20050706A2 (en) 2005-12-31
US20070053906A1 (en) 2007-03-08
AU2004216483A1 (en) 2004-09-10
CN100563712C (zh) 2009-12-02
BRPI0407649A (pt) 2006-02-21
KR20050105486A (ko) 2005-11-04
NO20054440L (no) 2005-09-26
MXPA05009135A (es) 2005-10-20

Similar Documents

Publication Publication Date Title
CA2649538C (en) Buffering agents for biopharmaceutical formulations
KR102100282B1 (ko) 항-프로락틴 수용체 항체 제제
AU2007307107B2 (en) Stable antibody formulations
EP4364724A2 (en) High concentration vegf receptor fusion protein containing formulations
UA82503C2 (ru) Жидкая композиция белка, который связывает фактор некроза опухолей
KR20170005864A (ko) 액체 제약 조성물
KR102735988B1 (ko) 치료 항체 제제
EP3888678A1 (en) Anti-pd-l1 antibody preparation
CN101795670A (zh) G-csf的液体制剂
AU2012200284B2 (en) Stable Antibody Formulations
JP7548475B1 (ja) 抗体製剤
CN120754244B (zh) 一种含抗cd19抗体的药物组合物及其用途
CA3129901C (en) Therapeutic antibody formulation
WO2024190892A1 (ja) 抗体製剤
AU2004216483B2 (en) Liquid formulations of tumor necrosis factor-binding proteins
KR20230026407A (ko) 액티빈 a 항체 제형 및 이의 사용 방법
AU2020364480A1 (en) Stable liquid composition, method for preparing same, and formulation comprising same
WO2014089957A1 (zh) 一种稳定的白消安注射剂
HK1085677B (en) Liquid formulations of tumor necrosis factor-binding proteins